
FDA Approves First Interchangeable Biosimilar for Omalizumab
The FDA has approved omalizumab-igec (OMLYCLO) as the first interchangeable biosimilar for reference omaliumab (Xolair) and the first respiratory biosimilar, for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal …